Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

The PI3K pathway itself can be mutated at different levels and different genes that are involved in the pathway can be mutated and altered, says Arteaga. Several inhibitors are in clinical development that hit the pathway at multiple points.

Arteaga predicts that the use of these inhibitors could become a standard of care in the near future.

Carlos Arteaga

Articles

Dr. Arteaga on PI3K Pathway Inhibitors